CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Recurrent Transformed Chronic Lymphocytic Leukemia · Refractory B-Cell Non-Hodgkin Lymphoma · Refractory Chronic Lymphocytic Leukemia · Refractory Small Lymphocytic Lymphoma · Refractory Transformed Chronic Lymphocytic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Saad J. Kenderian, M.D.)

Study leads

Saad J. Kenderian, M.D.
Principal Investigator
Mayo Clinic in Rochester

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Hodgkin Disease · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30+ Anaplastic Large Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Recurrent Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System Neoplasm · Histiocytic Sarcoma · Malignant Histiocytosis

Abroad (travel likely)RecruitingPHASE1

Scottsdale, United States · Rochester, United States

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

B-Cell Non-Hodgkin Lymphoma · Histiocytic and Dendritic Cell Neoplasm · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1

Scottsdale, United States · Rochester, United States